These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 26012491)

  • 1. Voxel-based morphometry of the marmoset brain: In vivo detection of volume loss in the substantia nigra of the MPTP-treated Parkinson's disease model.
    Hikishima K; Ando K; Komaki Y; Kawai K; Yano R; Inoue T; Itoh T; Yamada M; Momoshima S; Okano HJ; Okano H
    Neuroscience; 2015 Aug; 300():585-92. PubMed ID: 26012491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson Disease: Diffusion MR Imaging to Detect Nigrostriatal Pathway Loss in a Marmoset Model Treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Hikishima K; Ando K; Yano R; Kawai K; Komaki Y; Inoue T; Itoh T; Yamada M; Momoshima S; Okano HJ; Okano H
    Radiology; 2015 May; 275(2):430-7. PubMed ID: 25602507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurometabolic profiles of the substantia nigra and striatum of MPTP-intoxicated common marmosets: An in vivo proton MRS study at 9.4 T.
    Heo H; Ahn JB; Lee HH; Kwon E; Yun JW; Kim H; Kang BC
    NMR Biomed; 2017 Feb; 30(2):. PubMed ID: 28028868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the neuroprotective effects of modafinil in a marmoset Parkinson model with immunohistochemistry, magnetic resonance imaging and spectroscopy.
    van Vliet SA; Blezer EL; Jongsma MJ; Vanwersch RA; Olivier B; Philippens IH
    Brain Res; 2008 Jan; 1189():219-28. PubMed ID: 18076869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP model.
    Verhave PS; Jongsma MJ; Van Den Berg RM; Vanwersch RA; Smit AB; Philippens IH
    Neuropharmacology; 2012 Mar; 62(4):1700-7. PubMed ID: 22178201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset.
    Mackenzie GM; Jackson MJ; Jenner P; Marsden CD
    Synapse; 1997 Jul; 26(3):301-16. PubMed ID: 9183819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment.
    Korecka JA; Eggers R; Swaab DF; Bossers K; Verhaagen J
    Restor Neurol Neurosci; 2013; 31(2):155-67. PubMed ID: 23271419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage.
    Franke SK; van Kesteren RE; Wubben JA; Hofman S; Paliukhovich I; van der Schors RC; van Nierop P; Smit AB; Philippens IH
    Neuroscience; 2016 Jan; 312():247-59. PubMed ID: 26431624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection.
    Stephenson D; Ramirez A; Long J; Barrezueta N; Hajos-Korcsok E; Matherne C; Gallagher D; Ryan A; Ochoa R; Menniti F; Yan J
    J Neurosci Methods; 2007 Jan; 159(2):291-9. PubMed ID: 16949674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice.
    Patil SP; Jain PD; Ghumatkar PJ; Tambe R; Sathaye S
    Neuroscience; 2014 Sep; 277():747-54. PubMed ID: 25108167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective action of recombinant neurturin on dopaminergic neurons in substantia nigra in a rhesus monkey model of Parkinson's disease.
    Li H; He Z; Su T; Ma Y; Lu S; Dai C; Sun M
    Neurol Res; 2003 Apr; 25(3):263-7. PubMed ID: 12739234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism.
    Kozina EA; Khakimova GR; Khaindrava VG; Kucheryanu VG; Vorobyeva NE; Krasnov AN; Georgieva SG; Kerkerian-Le Goff L; Ugrumov MV
    J Neurol Sci; 2014 May; 340(1-2):198-207. PubMed ID: 24768159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of iron in Parkinson's disease monkeys assessed by susceptibility weighted imaging and inductively coupled plasma mass spectrometry.
    Li SJ; Ren YD; Li J; Cao B; Ma C; Qin SS; Li XR
    Life Sci; 2020 Jan; 240():117091. PubMed ID: 31760102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sparing of orexin-A and orexin-B neurons in the hypothalamus and of orexin fibers in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated macaques.
    Bensaid M; Tandé D; Fabre V; Michel PP; Hirsch EC; François C
    Eur J Neurosci; 2015 Jan; 41(1):129-36. PubMed ID: 25328140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesenchymal stem cells augment neurogenesis in the subventricular zone and enhance differentiation of neural precursor cells into dopaminergic neurons in the substantia nigra of a parkinsonian model.
    Park HJ; Shin JY; Lee BR; Kim HO; Lee PH
    Cell Transplant; 2012; 21(8):1629-40. PubMed ID: 22546197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease.
    Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU
    J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's disease.
    Modo M; Crum WR; Gerwig M; Vernon AC; Patel P; Jackson MJ; Rose S; Jenner P; Iravani MM
    PLoS One; 2017; 12(7):e0180733. PubMed ID: 28738061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced de novo neurogenesis and dopaminergic neurogenesis in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease-like mice.
    Shan X; Chi L; Bishop M; Luo C; Lien L; Zhang Z; Liu R
    Stem Cells; 2006 May; 24(5):1280-7. PubMed ID: 16424396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure fails to produce delayed degeneration of substantia nigra neurons in monkeys.
    Garrido-Gil P; Belzunegui S; San Sebastián W; Izal-Azcárate A; López B; Marcilla I; Luquin MR
    J Neurosci Res; 2009 Feb; 87(2):586-97. PubMed ID: 18798285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.